Abstract
The WHO Classification for Hodgkin’s disease (HD) has made an important step by separating nodular lymphocyte predominant HD, NLPHD, from classical HD subtypes.1, 2 Although uncommon, approximately 5% of all HD, NLPHD is important because of its unique morphologic/immunophenotypic features, as well as its clinical characteristics and evolving recommendations for therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
7. References
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November, 1997. Hematol J. 2000;1(1):53–66.
Harris NL. Hodgkin’s lymphomas: Classification, diagnosis, and grading. Semin Hematol. 1999;36:220–232.
Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES, Han J, van Krieken JM, Poppema S, Marafioti T, Franklin J, Sextro M, Diehl V, Stein H. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000 Sep 1;96(5):1889–99.
Ekstrand BC, Horning SJ. Lymphocyte predominant Hodgkin’s disease. Curr Oncol Rep. 2002 Sep;4(5):424–33.
Lin P, Medeiros LJ, Wilder RB, Abruzzo LV, Manning JT, Jones D. The activation profile of tumour-associated reactive T-cells differs in the nodular and diffuse patterns of lymphocyte predominant Hodgkin’s disease. Histopathology. 2004 Jun;44(6):561–9.
Ohno T, Huang JZ, Wu G, Park KH, Weisenburger DD, Chan WC. The tumor cells in nodular lymphocyte-predominant Hodgkin disease are clonally related to the large cell lymphoma occurring in the same individual. Direct demonstration by single cell analysis. Am J Clin Pathol. 2001 Oct;116(4):506–11.
Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, Poppema S, Harris M, Franssila K, van Krieken J, Marafioti T, Anagnostopoulos I, Stein H. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol. 1999 Mar;17(3):776–83.
Ripp JA, Loiue DC, Chan W, Nawaz H, Portlock CS. T-cell rich B-cell lymphoma: clinical distinctiveness and response to treatment in 45 patients. Leuk Lymphoma. 2002 Aug;43(8):1573–80.
Khoury JD, Jones D, Yared MA, Manning JT Jr, Abruzzo LV, Hagemeister FB, Medeiros LJ. Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol. 2004 Apr;28(4):489–95.
Miettinen M, Franssila KO, Saxen E. Hodgkin’s disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin’s lymphomas. Cancer. 1983 Jun 15;51(12):2293–300.
Pellegrino B, Terrier-Lacombe MJ, Oberlin O, Leblanc T, Perel Y, Bertrand Y, Beard C, Edan C, Schmitt C, Plantaz D, Pacquement H, Vannier JP, Lambilliote C, Couillault G, Babin-Boilletot A, Thuret I, Demeocq F, Leverger G, Delsol G, Landman-Parker J; Study of the French Society of Pediatric Oncology. Lymphocyte-predominant Hodgkin’s lymphoma in children: therapeutic abstention after initial lymph node resection-a Study of the French Society of Pediatric Oncology. J Clin Oncol. 2003 Aug 1;21(15):2948–52.
Murphy SB, Morgan ER, Katzenstein HM, Kletzel M. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol. 2003 Sep;25(9):684–7.
Wilder RB, Schlembach PJ, Jones D, Chronowski GM, Ha CS, Younes A, Hagemeister FB, Barista I, Cabanillas F, Cox JD. European Organization for Research and Treatment of Cancer and Groupe d’Etude des Lymphomes de l’Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer. 2002 Mar 15;94(6):1731–8.
Greer JP, Macon WR, Lamar RE, Wolff SN, Stein RS, Flexner JM, Collins RD, Cousar JB. T-cell-rich B-cell lymphomas: diagnosis and response to therapy of 44 patients. J Clin Oncol. 1995 Jul;13(7):1742–50.
Huang JZ, Weisenburger DD, Vose JM, Greiner TC, Aoun P, Chan WC, Lynch JC, Bierman PJ, Armitage JO; Nebraska Lymphoma Study Group. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma. 2003 Nov;44(11):1903–10.
Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, Natkunam Y, Bartlett NL, Horning SJ. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003 Jun 1;101(11):4285–9.
Bodis S, Kraus MD, Pinkus G, Silver B, Kadin ME, Canellos GP, Shulman LN, Tarbell NJ, Mauch PM. Clinical presentation and outcome in lymphocyte-predominant Hodgkin’s disease. J Clin Oncol. 1997 Sep;15(9):3060–6.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Portlock, C.S. (2006). Nodular Lymphocyte Predominant Hodgkin’s Disease. In: Leonard, J.P., Coleman, M. (eds) Hodgkin’s and Non-Hodgkin’s Lymphoma. Cancer Treatment and Research, vol 131. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-29346-2_12
Download citation
DOI: https://doi.org/10.1007/978-0-387-29346-2_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-29345-5
Online ISBN: 978-0-387-29346-2
eBook Packages: MedicineMedicine (R0)